We report a case of a patient with Systemic Lupus Erythematosus (SLE) complicated by the antiphospholipid syndrome and recurrent episodes of transverse myelitis. Transverse myelitis is a rare complication of SLE and most cases are associated with the presence of an antiphospholipid antibody (APA). The pathogenic mechanism oftransverse myelitis in this condition may result from a vasculitic process. However, the association with an APA suggests a thrombotic causation, hence consideration should be given to anticoagulant therapy in addition to established immunosuppressive treatment. This case also illustrates the value ofrecently developed enzyme linked immunosorbent assays for measuring anticardiolipin antibodies over previous methods available in Belfast particularly those employing the VDRL cardiolipin as antigen. CASEREPORT. A 58 year old Caucasian woman presented to the Rheumatology Unit with a 3 day history of progressive weakness and numbness in her legs, vague lower back pain and urinary incontinence. A diagnosis of systemic lupus erythematosus (SLE) had been made twelve years previously on the basis of arthritis, pleurisy, a "butterfly" facial rash and a positive antinuclear antibody. She described three similar episodes requiring hospital admission during the previous three years. On each occasion she had received oral corticosteroids, with gradual, albeit incomplete, improvement in her clinical condition. Examination showed severe weakness of the left lower limb and moderate weakness on the right in a pyramidal pattern. There was a sensory level to pinprick sensation below T8 on the right side and impaired posterior column sensation on the left. Deep tendon reflexes were increased in the lower limbs with bilateral extensor plantar responses. The cranial nerves and upper limbs were normal. These signs suggested an incomplete spinal cord lesion in the region of T8. Initial investigations were as follows: ESR 45mm/hr (Westergren); Full blood picture normal; C-reactive protein (CRP) 6mg/1 (normal range < 1 Omg/i); Renal function normal; Antinuclear antibody IgG 160, IgM 80; antinucleolar antibody IgG 320, IgM negative; antibody to double stranded DNA 6.6 (normal range 0-Smg/l); antibodies to Ro, La and Sm were all positive; pANCA 80, antimyeloperoxidase antibodies negative; immunoglobulins, C3, C4 and CH50 were all within the normal range with no circulating immune complexes detected. Antibody to anticardiolipin (VDRL Antigen) was negative on repeated testing. The ELISA test for anticardiolipin (aCL) was, retrospectively performed on 7 serum samples stored during the previous 2 years, with aCL IgG elevated on 2 of these occasions at levels of 24.2 and 32.7 GPL units/mL (normal range < 23) and aCL IgM elevated on one occasion at a level of 13.5 MPL units/mL (normal range < I 1). Visual and sensory
Transverse myelitis: a complication of systemic lupus erythematosus that is associated with the antiphospholipid syndrome A E Smyth, I N Bruce, S A McMillan*, A L Bell Accepted 6 March 1996 We report a case of a patient with Systemic Lupus Erythematosus (SLE) complicated by the antiphospholipid syndrome and recurrent episodes of transverse myelitis. Transverse myelitis is a rare complication of SLE and most cases are associated with the presence of an antiphospholipid antibody (APA) . The pathogenic mechanism oftransverse myelitis in this condition may result from a vasculitic process. However, the association with an APA suggests a thrombotic causation, hence consideration should be given to several benefits in that it can be used on banked frozen sera, anticoagulants do not affect results and identification and quantification of different aCL isotypes is possible. The ELISA is more sensitive at detecting aCL, thus manyregard it as the most clinically useful screening test. However, the LA test appears to be more specific for predicting clinical features other than transverse myelitis which has not been formally tested. Unfortunately, the ELISA test was not available in Belfast during this patient' s initial presentation and the elevated aCL was detected on banked frozen sera 2 years later. Sera from 94 healthy blood donors have been tested by the Sigma immunoassay currently used in Belfast; the mean + 2 SD (standard deviation) values obtained were 12 + 10.6 GPL units/mL for IgG and 5 + 5.6 MPL units/mL for IgM. The frequency of aCL positivity in SLE patients ranges from 17-61%."1 In a series of 95 Irish patients it was found to be 44%*.12 The pathogenic mechanisms underlying transverse myelitis are unknown, although vasculitis and ischaemia have been described at postmortemexamination.6" 3 The almost universal finding of antiphospholipid antibodies in such patients can be interpreted in different ways; for instance APA might simply result from inflammatory vascular damage. There is, however, good evidence that they contribute directly to a procoagulant state5 so that vascular occlusive myelitis secondary to thrombosis must be considered. Finally direct interaction between APA and spinal cord phospholipids in the presence of a co-factor, a B-2 glycoprotein I has been postulated.5 14 In our patient, vasculitis should not be assumed on the basis of the cerebral MRI findings, since similar appearances have been reported in primary APA syndrome9 and in addition she had no clinical features to suggest widespread lupus vasculitis.
The treatment regimes available include high dose steroids and immunosuppressive agents, which suppress the autoimmune response and inflammation involved in the vasculitic process. The value of isolated cases reported as showing improvement with plasma exchange and hydroxychloroquine have yet to be validated. In summary, this case emphasises the need to test for antiphospholipid antibodies, ideally by all three methods, in all patients presenting with transverse myelitis whether known to have SLE or not. As antibody levels vary with time and disease activity repeated measurements are advised.9 While consensus has yet to be reached on some aspects of treatment in the APS it is accepted that those individuals with elevated APA and a history of previous thrombosis require long term anticoagulation with warfarin. '4 15 Recent evidence suggests that maintenance of the INR at greater than 3.0 is required for secondary prevention of thrombosis in this condition. '6 While continuation of traditional treatment regimes for transverse myelitis are appropriate the presence of an elevated APA should alert the clinician to the possible thrombotic mechanism, and the need for the prompt initiation of adequate anticoagulation.
